{
  "drug_name": "Secnidazole",
  "tradename": "Solosec",
  "usage_and_dosing": {
    "general": [
      "Secnidazole is a nitroimidazole indicated for treatment of:",
      "Bacterial vaginosis in female patients ≥12 years of age.",
      "Trichomoniasis in patients ≥12 years of age.",
      "Because trichomoniasis is sexually transmitted, treat partners with the same dose and at the same time.",
      "Concurrent use of ethanol:",
      "No effect of secnidazole on aldehyde dehydrogenase activity in vitro.",
      "However, postmarketing observations of nausea, vomiting diarrhea, abdominal pain, dizziness, and headache with concomitant use of secnidazole and alcohol have been reported.",
      "Recommendation: avoid consumption of alcoholic beverages during treatment and for at least two days after completing therapy."
    ],
    "adult_dose": {
      "dose": "2 gm packet (granules) once orally, without regard to the timing of meals.",
      "same_dose": "Same dose for bacterial vaginosis and trichomoniasis.",
      "administration": [
          "Sprinkle packet contents on applesauce, yogurt or pudding. The granules will not dissolve. Consume all of the mixture within 30 minutes without chewing or crunching the granules.",
          "Do not dissolve granules in liquid. May follow with glass of water to aid swallowing."
      ]
    },
    "pediatric_dose": {
      "dose_age_gt_12_yrs": "2 gm po x1",
      "max_day": "2 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "17",
    "half_life_esrd": "No data",
    "dose_renal_function_normal": "2 gm single-dose",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": {
      "contraindications": [
          "Known hypersensitivity to other nitroimidazoles (metronidazole, tinidazole).",
          "Use in patients with Cockayne syndrome. Severe, irreversible hepatotoxicity with fatal outcomes have been reported after initiation of metronidazole (also a nitroimidazole) in patients with Cockayne syndrome."
      ],
      "warnings": [
          "Vulvovaginal candidiasis may develop during use, requiring antifungal therapy.",
          "Potential carcinogenicity seen in rodent studies. Avoid chronic use."
      ],
      "other": [
          "Vulvovaginal pruritus.",
          "GI: nausea, dysgeusia, vomiting, diarrhea, abdominal pain.",
          "Headache."
      ]
  },
  "pregnancy_risk": {
    "fda_risk_category": "No human data, safe in animals",
    "lactation": "Safety not established, avoid breastfeeding for 96 hours after dose",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": [
    "Bacteroides spp.",
    "Gardnerella vaginalis",
    "Prevotella spp.",
    "Mobiluncus spp.",
    "Megasphaera-like type I/II",
    "Trichomonas vaginalis"
  ],
  "pharmacology": {
    "pk_pd_index": "No data",
    "preparations": "Oral granules (2 gm packets)",
    "food_recommendation": "Granules ± food",
    "oral_absorption_percent": "No data",
    "tmax_hr": "4",
    "peak_serum_conc_ug_ml": "45.4 (2 gm po, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "<5",
    "volume_of_distribution_vd_l": "42 L",
    "avg_serum_half_life_hr": "17",
    "elimination": "Metabolized",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "1331.6 (2 gm po, 0-inf)"
  },
  "major_drug_interactions": [
      {
          "drug": "Ethanol",
          "effect": "GI symptoms, dizziness, headache",
          "management": "Avoid co-administration"
      }
  ]
}
